Lipoprotein(a) — Lp(a) — is a cholesterol-carrying particle with a powerful genetic component that directly drives risk for early atherosclerosis and calcific aortic valve disease. Because it is 80–90% determined by genetics and remains remarkably stable throughout life, the ESC/EAS 2022 Consensus recommends every adult be tested at least once in their lifetime. When elevated, Lp(a) becomes a causal driver of cardiovascular disease — not merely a marker of risk.
Analyzed in accredited Swedish clinical laboratories (ISO 15189). Used to support clinician-directed evaluation and monitoring. Not a stand-alone diagnosis.
If you have a family history of early heart attack, stroke, or valve disease — or if you are over 40 and want to know your absolute cardiovascular risk profile — an Lp(a) test is essential. Unlike most risk factors, Lp(a) is determined largely by your genes, not by your lifestyle choices. A single test reveals whether you carry a genetic burden that will influence your cardiovascular strategy for the rest of your life.
Standard Swedish healthcare (vårdcentralen) typically does not test Lp(a) unless there is a documented family history of early coronary disease or familial hypercholesterolemia. Because Lp(a) is causal — not merely correlative — testing once in a lifetime is recommended by the European Society of Cardiology and European Atherosclerosis Society, regardless of your other risk factors. This is a test about genetics, not about current habit.
Identifies genetic cardiovascular risk. Lp(a) is 80–90% heritable; knowing your level tells you whether you carry a lifelong, genetically driven burden independent of diet, exercise, or other modifiable factors.
Uncovers causal risk that lipid panels miss. A normal total cholesterol, LDL, or even normal ApoB does not rule out high Lp(a) — this particle is completely independent, and mendelian randomization evidence confirms it is causal for ASCVD.
Flags hidden valve disease risk. Elevated Lp(a) is a major independent risk factor for calcific aortic valve disease, a process that can begin decades before symptoms appear.
Guides aggressiveness of cholesterol management. When Lp(a) is high, clinical evidence and guidelines recommend more aggressive management of ApoB using statins, ezetimibe, PCSK9 inhibitors, and other tools — because you cannot lower Lp(a) itself, you must control the other atherogenic particles it works alongside.
Clarifies family risk. Because Lp(a) is inherited, knowing your result informs genetic counselling for siblings and children — they have a 50% chance of inheriting your variant if they share a parent with you.
Enables lifetime planning. Because Lp(a) is stable for life, a single test at any age (ideally before 40) provides a baseline that does not need retesting unless methodological changes occur.
The particle and its structure. Lp(a) is a cholesterol-carrying lipoprotein particle composed of an LDL-like core surrounded by a protein called apolipoprotein(a) — apo(a) — which is covalently linked to apoB-100. This apo(a) moiety is what makes Lp(a) unique. It shares structural homology with plasminogen, a key protein in the blood's fibrinolytic (clot-dissolving) system, which may explain some of Lp(a)'s atherogenic and thrombotic properties.
Why it matters biologically. Lp(a) particles are small and dense enough to penetrate the arterial endothelium and accumulate in the artery wall, where they oxidize and trigger a chronic inflammatory response that accelerates plaque formation. Because Lp(a) carries cholesterol and sits in plaque lesions, and because it shares structural similarity to plasminogen, elevated Lp(a) may also impair the body's ability to dissolve clots — potentially increasing both plaque formation and thrombotic risk simultaneously. The clinical evidence from Mendelian randomization studies confirms that Lp(a) is a causal driver of premature atherosclerosis and aortic valve calcification, not merely a marker of risk.
Genetic determination and stability. Lp(a) levels are determined almost entirely by a single genetic locus (the LPA gene), which means your Lp(a) is essentially fixed at birth. Unlike LDL cholesterol, which responds to diet, exercise, and medication, Lp(a) moves very little — it remains stable throughout adulthood barring rare methodological or laboratory changes. This makes it a powerful genetic risk marker but also a therapeutic challenge: there is currently no approved Lp(a)-lowering therapy on the market (though several candidates including olpasiran and pelacarsen are in phase 3 clinical trials).
Mendelian randomization confirms causality. Lp(a) is not merely associated with ASCVD — genetic studies confirm it is a causal risk factor. This means that even in the absence of other traditional risk factors, elevated Lp(a) drives atherosclerotic disease independent of LDL, inflammation, or metabolic syndrome.
Identifies discordant risk in people with "normal" lipid panels. Many people have a normal LDL or even normal ApoB but very high Lp(a), which puts them at significantly elevated cardiovascular risk. Without testing Lp(a), this causal risk is completely invisible.
Risk is very high above 180 mg/dL (450 nmol/L). Lp(a) above this threshold confers a cardiovascular risk approximately equivalent to heterozygous familial hypercholesterolemia (FH) — a genetic condition that traditionally triggers aggressive clinical intervention. Yet without testing, many people with this level of risk go unidentified.
Guides therapy intensity for life. Once you know your Lp(a), the clinical response is not to lower Lp(a) (impossible with current therapy) but to aggressively control ApoB and manage other modifiable factors. This strategy changes the intensity of statin therapy, the threshold for PCSK9 inhibitors, and the approach to cardiovascular prevention generally.
Lp(a) reference ranges are expressed in both European units (nmol/L, preferred) and North American units (mg/dL). European guidelines (ESC/EAS 2022 Consensus) define risk tiers as follows:
Low risk: <30 mg/dL (<75 nmol/L). This range is associated with low lifetime cardiovascular and valve disease risk attributable to Lp(a) alone.
Intermediate risk: 30–50 mg/dL (75–125 nmol/L). At this level, Lp(a) contributes measurably to cardiovascular risk, particularly when other factors (elevated ApoB, inflammation, metabolic dysfunction) are present.
High risk: 50–180 mg/dL (125–450 nmol/L). At this level, Lp(a) is a significant independent driver of atherosclerotic disease and warrants aggressive management of other modifiable risk factors (especially ApoB and hs-CRP).
Very high risk: >180 mg/dL (>450 nmol/L). This level confers cardiovascular risk similar to heterozygous familial hypercholesterolemia and demands intensive preventive strategies.
Because Lp(a) is genetically determined and stable, results do not shift meaningfully with diet, exercise, or even most medications. The goal is not to "optimize" Lp(a) itself — it cannot be lowered substantially with current therapy — but to identify whether you carry this genetic burden so that you can aggressively optimize the particles and factors you can control.
Low Lp(a) (<30 mg/dL). A low result means you do not carry a significant genetic burden from the Lp(a) locus. Your cardiovascular risk from Lp(a) is comparable to the general population. This does not mean you have zero cardiovascular risk — that depends on ApoB, hs-CRP, blood pressure, glycemic control, and other factors — but Lp(a) is not a driver of your personal risk. Lifestyle optimization remains important, but aggressive Lp(a)-focused intervention is not needed.
Intermediate Lp(a) (30–50 mg/dL). This range indicates a modest genetic predisposition to atherosclerosis via Lp(a). Risk is elevated but not extreme. The clinical implication is that you should be more aggressive about controlling ApoB and inflammation (hs-CRP) than someone with lower Lp(a), especially if you have other cardiovascular risk factors. This is the zone where lifestyle habits and medication adherence matter most.
High Lp(a) (50–180 mg/dL). A result in this range means Lp(a) is a substantial causal driver of your cardiovascular risk. Most clinical guidelines recommend that you maintain ApoB in the aggressive range (typically <0.65 g/L or <50 mg/dL) and that you consider statin therapy if not already on it, with possible escalation to ezetimibe or PCSK9 inhibitors depending on your full lipid profile and other risk factors. You should also address inflammation (hs-CRP) aggressively. Consider formal cardiovascular risk assessment and possibly imaging (coronary calcium score, carotid intima-media thickness) if not already done.
Very High Lp(a) (>180 mg/dL). This level is rare in the general population but confers very high lifetime risk for premature atherosclerosis and valve disease. Clinical evidence supports intensive lipid-lowering therapy (high-intensity statin plus ezetimibe, with strong consideration for PCSK9 inhibitors), aggressive inflammation control, rigorous blood pressure management, excellent glycemic control, and regular cardiovascular imaging. Family members should be tested, as they have a 50% chance of inheriting a similar high Lp(a) level. Some centres also consider aspirin for primary prevention at this level, based on evidence from the ASPREE-Lp(a) substudy.
Factors that influence Lp(a) interpretation. Lp(a) levels are remarkably stable and not significantly affected by acute illness, medications, fasting status, time of day, or recent exercise. Pregnancy may lower Lp(a) slightly due to volume expansion, but the effect is modest. Renal disease and some inflammatory states may modestly elevate Lp(a), though the effect is much smaller than the genetic determination. The interpretation of Lp(a) is straightforward: your genetic risk level is revealed by this single number, and it remains constant throughout life.
Genetics and the LPA locus. Approximately 90% of the variation in Lp(a) across the population is explained by common and rare variants in the LPA gene, which encodes apolipoprotein(a). Some variants are associated with very low Lp(a) (protective), while others confer extremely high levels. This is inherited in an autosomal codominant pattern — if both parents carry high-Lp(a) alleles, children inherit correspondingly high levels.
Apo(a) isoform size. The apo(a) component of Lp(a) comes in multiple isoforms of different sizes, determined by the number of Kringle IV repeats in the protein. Smaller isoforms are generally associated with higher Lp(a) levels. This is one mechanism by which genetics drives the variation — different people literally inherit different sized apo(a) isoforms.
Kidney disease (secondary effect). Chronic kidney disease can modestly elevate Lp(a), likely due to reduced clearance, but this effect is small compared to the genetic determination. Lp(a) elevation in kidney disease is not typically the primary lipid target — controlling ApoB and inflammation remains the focus.
Acute inflammation or infection. Severe acute infection or inflammatory states may transiently raise Lp(a) slightly, but these changes are small and resolve with the underlying condition. This is not a major driver of Lp(a) variation in the population.
Estrogen status (modest effect). Some evidence suggests that estrogen may lower Lp(a) slightly, which may explain why premenopausal women sometimes have lower Lp(a) than men of similar genetic background. Menopause and hormonal changes may lead to small increases in Lp(a). However, the genetic determination dominates, and hormonal changes produce only modest shifts.
The central reality: Lp(a) itself cannot be lowered with current approved therapies. Unlike LDL cholesterol or triglycerides, Lp(a) is genetically fixed and does not respond meaningfully to diet, exercise, weight loss, or any available pharmaceutical. This is not a limitation of the person — it is a limitation of current medicine. Several compounds (olpasiran, pelacarsen, others) are in late-stage clinical trials and may become available in coming years, but they are not yet approved.
The clinical response: aggressive management of ApoB and other modifiable factors. When Lp(a) is elevated, the therapeutic strategy shifts to controlling the particles and factors that interact with Lp(a) to drive disease. This includes:
ApoB-lowering therapy. Statins inhibit HMG-CoA reductase and upregulate hepatic LDL receptors, pulling ApoB-containing particles out of circulation. Ezetimibe blocks intestinal cholesterol absorption, forcing the liver to pull more cholesterol from the blood. PCSK9 inhibitors prevent the degradation of LDL receptors, further increasing their numbers on hepatocytes. These therapies work synergistically — when Lp(a) is high, guidelines recommend reaching an ApoB target of <0.65 g/L (ideally <50 mg/dL) rather than the standard target for lower-risk individuals.
Inflammation control. Because Lp(a) particles are pro-inflammatory and accumulate in plaques, controlling systemic inflammation (via hs-CRP) matters. This is achieved primarily through lifestyle (quality sleep, regular movement, stress management, Mediterranean-pattern nutrition rich in polyphenols) and, where appropriate, through anti-inflammatory medication such as colchicine or high-dose statins (which have anti-inflammatory effects independent of LDL-lowering).
Blood pressure and glucose control. Hypertension accelerates atherosclerosis; elevated blood glucose accelerates endothelial dysfunction. These are modifiable and become more important when Lp(a) is high.
Aspirin for primary prevention. The ASPREE-Lp(a) substudy found modest benefit from aspirin in reducing cardiovascular events in individuals with elevated Lp(a), though the absolute benefit is small and aspirin carries bleeding risk. Discussion with a clinician is warranted if Lp(a) is very high (>180 mg/dL).
On niacin: Niacin does lower Lp(a) modestly (by 20–30% in some studies), but it raises uric acid and worsens glucose tolerance, and large RCTs have not shown that it reduces cardiovascular events. It is not recommended as a primary tool for Lp(a) management. The right strategy depends on the individual's full biomarker profile, family history, and risk factors — this is precisely the conversation a Loovi longevity doctor works through in consultation.
Lp(a) tells you about your genetic risk, but it is only one piece of the cardiovascular puzzle. A single elevated Lp(a) in the context of low ApoB and low hs-CRP means something very different from elevated Lp(a) paired with elevated ApoB and high inflammation. You also need to know your glycemic control (HbA1c, fasting glucose), your HDL and triglycerides, your blood pressure, your fitness level, and your family history of disease. Some of these are modifiable; Lp(a) is not. The full picture determines the aggressiveness of your cardiovascular strategy.
Moreover, knowing you have high Lp(a) without understanding your other lipid particles and inflammatory status can lead to either false reassurance ("my Lp(a) is high, but my LDL is normal" — actually, LDL and Lp(a) are independent, and both can be harmful) or unnecessary alarm (elevated Lp(a) alone, without elevated ApoB or inflammation, does not automatically demand immediate intensive therapy, though it does demand monitoring and preventive lifestyle).
This is where Loovi's comprehensive approach shines. A full panel of 120+ biomarkers — measured annually and contextualized by a longevity doctor — lets you see the entire system. You learn whether your Lp(a) is your primary risk driver, or whether your real issue is uncontrolled inflammation, insulin resistance, or metabolic dysfunction. You get a personalized health plan based on your unique biology, not a generic protocol. And you have direct access to a doctor to discuss what Lp(a) means for your specific life and family history. That is prevention done right.
No. Lp(a) and LDL are completely independent particles. LDL is a smaller lipoprotein particle; Lp(a) is LDL with an additional apo(a) protein attached. You can have high LDL with low Lp(a), or vice versa. The genetic loci that determine these particles are different, and they respond differently to diet and medication. Both are atherogenic, but Lp(a) has unique properties (structural similarity to plasminogen, possible thrombotic effects) that make it particularly dangerous.
This is an important discordance. It means your genetic risk from Lp(a) is significant, but your LDL cholesterol — which is what standard lipid panels measure — looks fine. Standard screening would miss this risk. The clinical response is to still manage your ApoB aggressively (which counts all atherogenic particles, not just LDL) and to monitor inflammation and other markers. Do not be falsely reassured by a normal LDL if your Lp(a) is high.
No. Lp(a) is genetically determined and remarkably stable. Diet and exercise do not meaningfully change it. This is not a failure on your part — it is the biology of Lp(a). You cannot diet your way out of a high Lp(a), but you absolutely can manage the other particles and risk factors that work alongside it (ApoB, inflammation, blood pressure, glucose control).
Yes. Because Lp(a) is inherited in an autosomal codominant pattern, if you carry high-Lp(a) alleles, your children have a 50% chance of inheriting a similarly high level (25% if only one parent carries high-Lp(a) alleles). Siblings have a 25% chance, assuming you share two parents. Testing family members early allows for identification of risk and early intervention — particularly important in children, where lifetime atherosclerotic burden can be substantially reduced by longstanding ApoB control and lifestyle optimization.
Standard vårdcentralen does not routinely test Lp(a) unless there is documented familial hypercholesterolemia or a personal or family history of premature coronary disease. If you want population screening or testing without clear clinical indication, it is usually available through private longevity services such as Loovi. The ESC/EAS 2022 Consensus recommends that every adult be tested at least once in their lifetime, but adoption of this recommendation in standard care remains incomplete.
No. Because Lp(a) is stable throughout life, a single test is sufficient. You do not need to retest in 6 months or yearly. The one exception is if there is a significant methodological change at your laboratory (e.g., they switch to a new assay or a new isoform-insensitive method) — in that case, one retest would be reasonable to establish your new baseline.
Isoform-sensitive assays (older methods) measure different apo(a) isoforms with different efficiency, which can lead to errors when comparing results between individuals or over time. Isoform-insensitive assays (newer methods) measure Lp(a) concentration uniformly regardless of apo(a) isoform size. When possible, isoform-insensitive assays are preferred because they give more accurate, comparable results. Ask your laboratory whether they use an isoform-insensitive method — ideally, they do.
No. Very high Lp(a) (e.g., >180 mg/dL) is a major risk factor, similar to heterozygous familial hypercholesterolemia, but it does not guarantee disease. Individual risk also depends on ApoB, inflammation, blood pressure, glucose control, fitness, sleep quality, stress, and other factors. Some people with very high Lp(a) and excellent control of other factors have less disease than expected; others have more. This is why comprehensive biomarker testing and personalized planning — not just Lp(a) alone — matter.
No. Statins, ezetimibe, PCSK9 inhibitors, and other standard lipid-lowering drugs do not meaningfully lower Lp(a). These drugs work on LDL and ApoB metabolism, which is separate from Lp(a) determination. They are still important — they control the other atherogenic particles — but they do not solve the Lp(a) problem. This is why new therapies (olpasiran, pelacarsen) are being developed specifically to lower Lp(a) by reducing apo(a) production in the liver.
The ESC/EAS consensus is that every adult should be tested at least once in their lifetime. Age alone is not a disqualifier. A young person with high Lp(a) and no family history of early disease might seem low-risk, but their lifetime risk is actually substantially elevated — and knowing this early allows for decades of preventive optimization. Conversely, a young person with low Lp(a) can be reassured that they do not carry this genetic burden.
